Joi + Blokes review

Joi + Blokes publishes $150 for a one-month nasal NAD⁺ subscription and $400 for a ten-week injected NAD⁺ subscription. Sermorelin is $559 for a 12-week subscription supply. TRT is advertised from $99/month, with quarterly billing language, a $75 start callout and a required initial lab and visit. Terms name possible pharmacy partners, but the dispenser for a selected medicine is unknown. State exclusions and first debit matter more than the monthly equivalents.

Joi and Blokes are parallel women’s and men’s telehealth programs. The longevity shelf includes sermorelin injections, NAD⁺ nasal spray and injections, glutathione and other products. Terms describe contracted medical practices and name potential fulfillment partners including Strive, Pharmacy Hub, Tailor Made Compounding, Cadre Labs, Empower, GiftHealth and Partell, without assigning a pharmacy to each order. The checked terms do not clearly identify a single legal corporate operator.

The TRT page requires an initial lab and clinician visit, and says follow-up visits and quarterly labs are included in treatment. An initial diagnostic panel is separately advertised at $149; the $99/month TRT callout does not establish that initial testing is included. TRT is unavailable in AL, AR, CT, DE, GA, HI, LA, MN, MO, MS, NC, ND, OK, PA, RI and SC according to its product page. New York and New Jersey may carry different pricing. Prescription sales and lab sales are final under the refund policy, and canceled hormone subscriptions are not refunded. The site does not bill insurance directly, although some pharmacy-routed drugs may use it.

Nasal NAD⁺ is $150 for a one-month subscription supply or $187 one-time. Injected NAD⁺ is $400 for a ten-week subscription supply (displayed as about $172/month equivalent) or $500 one-time; the $150 floor is for nasal, not injectable NAD⁺. Sermorelin is $559 for a 12-week subscription supply (about $186.33/month equivalent) or $699 one-time, while navigation tiles round to $199/month. TRT is advertised from $99/month with quarterly billing language and a separate $75 start callout; the initial lab/visit debit is not established. Enclomiphene also advertises a $99 monthly equivalent billed quarterly. Confirm the first charge, route, supply and state price before paying.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Terms name possible pharmacy partners but not the selected order’s dispenser, and no NABP or PCAB accreditation is shown — compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, this menu spans a wide range and the site does not grade it. Testosterone replacement has a genuine evidence base for treating diagnosed hypogonadism, together with real monitoring requirements — hematocrit and PSA among them — and it suppresses fertility, which is why enclomiphene being offered alongside it at the same price is a meaningful option rather than a marketing tier. Sermorelin acts on the growth-hormone axis, a real mechanism with thin long-term outcome data and no controlled trial behind the body-composition claims. Injected NAD⁺ has no controlled human outcome trials; the oral precursors NR and NMN are the studied forms and raise blood NAD⁺, a biomarker rather than a benefit. Injectable glutathione and topical GHK-Cu have essentially no controlled human outcome evidence. Rapamycin and VIP are prescribed off-label for longevity purposes without outcome trials in healthy people. On the GLP-1 side, everything in the headline program is compounded and therefore not FDA-approved, with brand-name options handled separately. Individual results vary.